A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial
Open accessThe DOI matches its Crossref record; 155 of the 160 references it cites were found in a registry or an index.
Abstract
Background: Insulin is generally administered to people with type 1 diabetes mellitus (T1DM) using multiple daily injections (MDIs), but can also be delivered using infusion pumps. In the UK, pumps are recommended for patients with the greatest need and adult use is less than in comparable countries. Previous trials have been small, of short duration and have failed to control for training in insulin adjustment. Objective: To assess the clinical effectiveness and cost-effectiveness of pump therapy compared with MDI for adults with T1DM, with both groups receiving equivalent structured training in flexible insulin therapy. Design: Pragmatic, multicentre, open-label, parallel-group cluster randomised controlled trial, including economic and psychosocial evaluations. After participants were assigned a group training course, courses were randomly allocated in pairs to either pump or MDI. Setting: Eight secondary care diabetes centres in the UK. Participants: Adults with T1DM for > 12 months, willing to undertake intensive insulin therapy, with no preference for pump or MDI, or a clinical indication for pumps. Interventions: Pump or MDI structured training in flexible insulin therapy, followed up for 2 years. MDI participants used insulin analogues. Pump participants used a Medtronic Paradigm®Veo TM(Medtronic, Watford, UK) with insulin aspart (NovoRapid, Novo Nordisk, Gatwick, UK). Main outcome measures: Primary outcome – change in glycated haemoglobin (HbA 1c) at 2 years in participants whose baseline HbA 1c was ≥ 7.5% (58 mmol/mol). Key secondary outcome – proportion of participants with HbA 1c≤ 7.5% at 2 years. Other outcomes at 6, 12 and 24 months – moderate and severe hypoglycaemia; insulin dose; body weight; proteinuria; diabetic ketoacidosis; quality of life (QoL); fear of hypoglycaemia; treatment satisfaction; emotional well-being; qualitative interviews with participants and staff (2 weeks), and participants (6 months); and ICERs in trial and modelled estimates of cost-effectiveness. Results: We randomised 46 courses comprising 317 participants: 267 attended a Dose Adjustment For Normal Eating course (132 pump; 135 MDI); 260 were included in the intention-to-treat analysis, of which 235 (119 pump; 116 MDI) had baseline HbA 1c of ≥ 7.5%. HbA 1c and severe hypoglycaemia improved in both groups. The drop in HbA 1c% at 2 years was 0.85 on pump and 0.42 on MDI. The mean difference (MD) in HbA 1c change at 2 years, at which the baseline HbA 1c was ≥ 7.5%, was –0.24% [95% confidence interval (CI) –0.53% to 0.05%] in favour of the pump (p = 0.098). The per-protocol analysis showed a MD in change of –0.36% (95% CI –0.64% to –0.07%) favouring pumps (p = 0.015). Pumps were not cost-effective in the base case and all of the sensitivity analyses. The pump group had greater improvement in diabetes-specific QoL diet restrictions, daily hassle plus treatment satisfaction, statistically significant at 12 and 24 months and supported by qualitative interviews. Limitation: Blinding of pump therapy was not possible, although an objective primary outcome was used. Conclusion: Adding pump therapy to structured training in flexible insulin therapy did not significantly enhance glycaemic control or psychosocial outcomes in adults with T1DM. Research priority: To understand why few patients achieve a HbA 1c of < 7.5%, particularly as glycaemic control is worse in the UK than in other European countries. Trial registration: Current Controlled Trials ISRCTN61215213. Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 21, No. 20. See the NIHR Journals Library website for further project information.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intensive glycemic control with insulin therapy reduces the risk of these complications.200,1122,1123”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1123]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
The Discovery of Grounded Theory; Strategies for Qualitative Research
Glaser, B. G., Strauss, A. L., & Strutzel, E. (1968) · Nursing Research · doi:10.1097/00006199-196807000-00014 · Cited by 39,449
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Basics of Qualitative Research: Grounded Theory Procedures and Techniques
Long, D. R., Strauss, A., & Corbin, J. (1993) · The Modern Language Journal · doi:10.2307/328955 · Cited by 17,576
WARE, J. E., KOSINSKI, M., & KELLER, S. D. (1996) · Medical Care · doi:10.1097/00005650-199603000-00003 · Cited by 17,392 · cited 1×
“The scores were standardised and scaled to range from 0 to 100, with higher scores representing better outcomes.(129,137)”
BackgroundEuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
An Efficient Method of Estimating Seemingly Unrelated Regressions and Tests for Aggregation Bias
Zellner, A. (1962) · Journal of the American Statistical Association · doi:10.1080/01621459.1962.10480664 · Cited by 8,401
Development of the World Health Organization WHOQOL-BREF Quality of Life Assessment
THE WHOQOL GROUP (1998) · Psychological Medicine · doi:10.1017/s0033291798006667 · Cited by 7,933
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Cross-Validation of Item Selection and Scoring for the SF-12 Health Survey in Nine Countries
Gandek, B., Ware, J. E., Aaronson, N. K., Apolone, G., Bjorner, J. B., Brazier, J. E., Bullinger, M., Kaasa, S., Leplege, A., Prieto, L., et al. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00109-7 · Cited by 2,907 · cited 1×
“The scores were standardised and scaled to range from 0 to 100, with higher scores representing better outcomes.(129,137)”
BackgroundCribari-Neto, F., & Zeileis, A. (2010) · Journal of Statistical Software · doi:10.18637/jss.v034.i02 · Cited by 2,505 · cited 1×
“The effect of pump + DAFNE treatment compared with MDI + DAFNE treatment on HbA1c was estimated using a beta regression.(123) Beta regressions estimate outcome parameters, which are bound by, but do include, a range of 0–1.”
MethodPope, C., & Mays, N. (1995) · BMJ · doi:10.1136/bmj.311.6996.42 · Cited by 2,336
Qualitative Research: Qualitative interviews in medical research
Britten, N. (1995) · BMJ · doi:10.1136/bmj.311.6999.251 · Cited by 1,670
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Self-citationThe Estimation of a Preference-Based Measure of Health From the SF-12
Brazier, J. E., & Roberts, J. (2004) · Medical Care · doi:10.1097/01.mlr.0000135827.18610.0d · Cited by 1,292 · cited 1×
“In a scenario analysis, utility values measured using the Short Form questionnaire-6 Dimensions (SF-6D) (a measure derived from the SF-12) were used to calculate QALY values.(104)”
MethodManca, A., Hawkins, N., & Sculpher, M. J. (2005) · Health Economics · doi:10.1002/hec.944 · Cited by 1,024 · cited 1×
“Baseline utility was included as a covariate to estimate QALYs so that any baseline differences in health between the two treatment arms was controlled for.(106) For the cost outcome variables, baseline HbA1c, centre, treatment allocation and baseline resource use were included as covariates, and clustering was contro…”
MethodCosts, effects and C/E‐ratios alongside a clinical trial
Van Hout, B. A., Al, M. J., Gordon, G. S., & Rutten, F. F. H. (1994) · Health Economics · doi:10.1002/hec.4730030505 · Cited by 964 · cited 1×
“The cost-effectiveness acceptability curve presented in Figure 18 shows the probability that pump + DAFNE and MDI + DAFNE are cost-effective across a range of cost-effectiveness thresholds.(152) It is clear that MDI + DAFNE has a higher probability of being cost-effective than pump + DAFNE at all cost-effectiveness th…”
BackgroundEffectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002853 · Cited by 894
Risk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration
UK Hypoglycaemia Study Group (2007) · Diabetologia · doi:10.1007/s00125-007-0599-y · Cited by 825
Amiel, S. A., Beveridge, S., Bradley, C., Gianfrancesco, C., Heller, S. R., James, P., McKeown, N., Newton, D. F., Newton, L. D., Oliver, L., et al. (2002) · Deakin Research Online (Deakin University) · Cited by 723
Self-citationThreshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652 · cited 1×
“The trial was sponsored by Medtronic, and Medtronic staff were involved in data analysis and editorial assistance.(74) The trial showed no difference in HbA1c after 3 months, perhaps not surprisingly because the baseline HbA1c was very good at 7.”
MethodBritish National Formulary: BNF
(2015) · doi:10.18578/bnf_147942626 · Cited by 641
The English Indices of Deprivation 2010
McLennan, D., Barnes, H., Noble, M., Davies, J., Garrett, E., & Dibben, C. J. L. (2011) · Cited by 591
Brookes, S. T., Whitley, E., Peters, T. J., Mulheran, P. A., Egger, M., & Davey Smith, G. (2001) · Health Technology Assessment · doi:10.3310/hta5330 · Cited by 580 · cited 1×
“Subgroup analysis Pre-planned subgroup analyses were undertaken and regarded as exploratory; significant results from the analysis were interpreted with caution, as recommended for subgroup analyses.(95) The following subgroups were investigated:”
MethodFear of hypoglycemia: quantification, validation, and utilization
Cox, D. J., Irvine, A., Gonder-Frederick, L., Nowacek, G., & Butterfield, J. (1987) · Diabetes Care · doi:10.2337/diacare.10.5.617 · Cited by 579 · cited 1×
“Hypoglycaemia Fear Survey The HFS behaviour and worry scores were calculated if at least 80% of items within that domain were complete, using Equation 5 (see Diabetes-specific quality of life).(131)”
MethodDonovan, J., Little, P., Mills, N., Smith, M., Brindle, L., Jacoby, A., Peters, T., Frankel, S., Neal, D., & Hamdy, F. (2002) · BMJ · doi:10.1136/bmj.325.7367.766 · Cited by 533
Estimating Utility Values for Health States of Type 2 Diabetic Patients Using the EQ-5D (UKPDS 62)
Clarke, P., Gray, A., & Holman, R. (2002) · Medical Decision Making · doi:10.1177/027298902400448902 · Cited by 515
Pickup, J., Mattock, M., & Kerry, S. (2002) · BMJ · doi:10.1136/bmj.324.7339.705 · Cited by 483
What can qualitative research do for randomised controlled trials? A systematic mapping review
O'Cathain, A., Thomas, K. J., Drabble, S. J., Rudolph, A., & Hewison, J. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-002889 · Cited by 438 · cited 1×
“It is common practice for qualitative research to be undertaken with patients and staff who are involved in clinical trials.(161,162) This research usually takes place during a trial’s pilot or early phases to improve recruitment, patients’ understanding of trial processes and the solicitation of informed consent.”
MethodLy, T. T., Nicholas, J. A., Retterath, A., Lim, E. M., Davis, E. A., & Jones, T. W. (2013) · JAMA · doi:10.1001/jama.2013.277818 · Cited by 411 · cited 2×
“The other trial of the Veo was by Ly et al.(75) in Australia.”
BackgroundMethodMisso, M. L., Egberts, K. J., Page, M., O'Connor, D., & Shaw, J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005103.pub2 · Cited by 406 · cited 2×
“is a trial – the paper does not mention randomisation but Misso et al.(31) in the Cochrane review say it was a RCT and that it had access to unpublished data) had a duration of ≥ 12 months, and none used analogue MDI.”
MethodContinuous Subcutaneous Insulin Infusion at 25 Years
Pickup, J., & Keen, H. (2002) · Diabetes Care · doi:10.2337/diacare.25.3.593 · Cited by 397
Valuing Health-Related Quality of Life in Diabetes
Coffey, J. T., Brandle, M., Zhou, H., Marriott, D., Burke, R., Tabaei, B. P., Engelgau, M. M., Kaplan, R. M., & Herman, W. H. (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2238 · Cited by 379
Jeitler, K., Horvath, K., Berghold, A., Gratzer, T. W., Neeser, K., Pieber, T. R., & Siebenhofer, A. (2008) · Diabetologia · doi:10.1007/s00125-008-0974-3 · Cited by 375
Horvath, K., Jeitler, K., Berghold, A., Ebrahim, S. H., Gratzer, T. W., Plank, J., Kaiser, T., Pieber, T. R., & Siebenhofer, A. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005613.pub3 · Cited by 366 · cited 1×
“Systematic reviews of clinical trials of insulin analogues involving people with T1DM have reported only minor advantages compared with human insulin, with a reduced risk of symptomatic hypoglycaemia, particularly at night.(3,4) This may be, in part, because those people who are at the greatest risk of hypoglycaemia a…”
BackgroundDahl-Jørgensen, K., Brinchmann-Hansen, O., Hanssen, K. F., Sandvik, L., & Aagenaes, O. (1985) · BMJ · doi:10.1136/bmj.290.6471.811 · Cited by 360 · cited 1×
“Dahl-Jørgensen et al.(54) reported a steep drop in HbA1c with a plateau after 3 months, but this reduction started in the 2-month run-in period before pump therapy was started.”
BackgroundCummins, E., Royle, P., Snaith, A., Greene, A., Robertson, L., McIntyre, L., & Waugh, N. (2010) · Health Technology Assessment · doi:10.3310/hta14110 · Cited by 335 · cited 2×
“They identified four cost-effectiveness studies in the UK setting, three of which presented an incremental cost-effectiveness ratio (ICER).(9,14,20,21) The ICERs in these studies were £11,461 per quality-adjusted life-year (QALY) gained, £25,648 per QALY gained and £37,712 per QALY gained.”
BackgroundSelf-citationDahl-Jorgensen, K., Brinchmann-Hansen, O., Hanssen, K. F., Ganes, T., Kierulf, P., Smeland, E., Sandvik, L., & Aagenaes, O. (1986) · BMJ · doi:10.1136/bmj.293.6556.1195 · Cited by 329
Qualitative research methods in general practice and primary care
Britten, N., Jones, R., Murphy, E., & Stacy, R. (1995) · Family Practice · doi:10.1093/fampra/12.1.104 · Cited by 272 · cited 1×
“In-depth interviews were used to collect data about staff experiences of study closeout, as these afforded the flexibility needed for participants to raise and discuss issues that they perceived as being salient, including those unforeseen at the study’s outset.(142,174) The use of one-to-one interviews also afforded…”
MethodM�hlhauser, I., J�rgens, V., Berger, M., Graninger, W., G�rtler, W., Hornke, L., Kunz, A., Schernthaner, G., Scholz, V., & Voss, H. E. (1983) · Diabetologia · doi:10.1007/bf00284453 · Cited by 269
Donovan, J. L., Paramasivan, S., de Salis, I., & Toerien, M. (2014) · Trials · doi:10.1186/1745-6215-15-5 · Cited by 262
Mühlhauser, I., Bruckner, I., Berger, M., Cheţa, D., Jörgens, V., Ionescu-Tîrgovişte, C., Scholz, V., & Mincu, I. (1987) · Diabetologia · doi:10.1007/bf00296989 · Cited by 262
(2015) · doi:10.1136/bmj.h3234 · Cited by 258 · cited 2×
“Steineck et al.(66) from Sweden reported mortality data from a cohort of 18,168 people with T1DM in Sweden, of whom 13% were on pump therapy.”
BackgroundMethodBode, B. W., Steed, R. D., & Davidson, P. C. (1996) · Diabetes Care · doi:10.2337/diacare.19.4.324 · Cited by 257
Review of Utility Values for Economic Modeling in Type 2 Diabetes
Beaudet, A., Clegg, J., Thuresson, P.-O., Lloyd, A., & McEwan, P. (2014) · Value in Health · doi:10.1016/j.jval.2014.03.003 · Cited by 256 · cited 1×
“For the independent analysis, a systematic review of utilities in type 2 diabetes mellitus published in 2014 by Beaudet et al.(113) was used for many of the health states of their economic model.”
MethodHoogma, R. P. L. M., Hammond, P. J., Gomis, R., Kerr, D., Bruttomesso, D., Bouter, K. P., Wiefels, K. J., De La Calle, H., Schweitzer, D. H., Pfohl, M., et al. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01738.x · Cited by 255
Self-citationClinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes
Colquitt, J., Green, C., Sidhu, M., Hartwell, D., & Waugh, N. (2004) · Health Technology Assessment · doi:10.3310/hta8430 · Cited by 249 · cited 2×
“A previous HTA report identified some gains in QoL that could be described as ‘social related’ rather than ‘health related’.(14) These included flexibility of lifestyle and fewer problems dealing with variations in daily life, such as timing of meals.”
BackgroundSelf-citation1998 Standard Occupational Classification
Salmon, L. (1999) · Industrial Relations: A Journal of Economy and Society · doi:10.1111/0019-8676.00126 · Cited by 246
Clarke, P., Gray, A., Legood, R., Briggs, A., & Holman, R. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.00972.x · Cited by 246
Recall of severe hypoglycaemia and self‐estimated state of awareness in type 1 diabetes
Pedersen‐Bjergaard, U., Pramming, S., & Thorsteinsson, B. (2003) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.377 · Cited by 240 · cited 1×
“The number of severe episodes are reliably recorded by patients for up to 1 year.(91)”
BackgroundFeatherstone, K., & Donovan, J. L. (2002) · Social Science & Medicine · doi:10.1016/s0277-9536(01)00197-6 · Cited by 230
Sämann, A., Mühlhauser, I., Bender, R., Kloos, C., & Müller, U. A. (2005) · Diabetologia · doi:10.1007/s00125-005-1905-1 · Cited by 226 · cited 1×
“Importantly, trials and observational studies of high-quality training alone (with standard insulin injections) show benefits in blood glucose control, hypoglycaemia and QoL, which are as good, if not better, than those reported after pump therapy.(2,25,26)”
BackgroundFatourechi, M. M., Kudva, Y. C., Murad, M. H., Elamin, M. B., Tabini, C. C., & Montori, V. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1415 · Cited by 221
Validation of a Diabetes-Specific Quality-of-Life Scale for Patients With Type 1 Diabetes
Bott, U., Mühlhauser, I., Overmann, H., & Berger, M. (1998) · Diabetes Care · doi:10.2337/diacare.21.5.757 · Cited by 204 · cited 1×
“Diabetes-specific QoL was assessed using the DSQOL, a reliable and valid measure.(127) Specifically designed for the German study on which UK DAFNE is based, it was included to facilitate important comparisons between the UK and German studies.”
MethodHirsch, I. B., Bode, B. W., Garg, S., Lane, W. S., Sussman, A., Hu, P., Santiago, O. M., Kolaczynski, J. W., & for the Insulin Aspart CSII/MDI Comparison Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.3.533 · Cited by 197
DeVries, J. H., Snoek, F. J., Kostense, P. J., Masurel, N., Heine, R. J., & On behalf of the Dutch Insulin Pump Study Group (2002) · Diabetes Care · doi:10.2337/diacare.25.11.2074 · Cited by 187
Schiffrin, A., & Belmonte, M. M. (1982) · Diabetes · doi:10.2337/diab.31.3.255 · Cited by 177
continuous Subcutaneous Insulin Infusion in the Treatment of Diabetes Mellitus
Pickup, J. C., Keen, H., Viberti, G. C., White, M. C., Kohner, E. M., Parsons, J. A., & Alerti, K. G. M. M. (1980) · Diabetes Care · doi:10.2337/diacare.3.2.290 · Cited by 175
Insulin Pump Therapy With Automated Insulin Suspension in Response to Hypoglycemia
Choudhary, P., Shin, J., Wang, Y., Evans, M. L., Hammond, P. J., Kerr, D., Shaw, J. A. M., Pickup, J. C., & Amiel, S. A. (2011) · Diabetes Care · doi:10.2337/dc10-2411 · Cited by 175
Self-citationHanaire-Broutin, H., Melki, V, Bessières-Lacombe, S., & Tauber, J. P. (2000) · Diabetes Care · doi:10.2337/diacare.23.9.1232 · Cited by 174
Hermanides, J., Nørgaard, K., Bruttomesso, D., Mathieu, C., Frid, A., Dayan, C. M., Diem, P., Fermon, C., Wentholt, I. M. E., Hoekstra, J. B. L., et al. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03256.x · Cited by 169
Donovan, J. L., de Salis, I., Toerien, M., Paramasivan, S., Hamdy, F. C., & Blazeby, J. M. (2014) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2014.03.010 · Cited by 161
Medicines for human use (clinical trials) regulations 2004.
(2004) · PubMed · Cited by 161
Speight, J., Amiel, S. A., Bradley, C., Heller, S., Oliver, L., Roberts, S., Rogers, H., Taylor, C., & Thompson, G. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.03.017 · Cited by 160
Self-citationStructured Type 1 Diabetes Education Delivered Within Routine Care
Cooke, D., Bond, R., Lawton, J., Rankin, D., Heller, S., Clark, M., Speight, J., & for the U.K. NIHR DAFNE Study Group (2013) · Diabetes Care · doi:10.2337/dc12-0080 · Cited by 156
Self-citationPlank, J., Siebenhofer, A., Berghold, A., Jeitler, K., Horvath, K., Mrak, P., & Pieber, T. R. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1337 · Cited by 141 · cited 1×
“Systematic reviews of clinical trials of insulin analogues involving people with T1DM have reported only minor advantages compared with human insulin, with a reduced risk of symptomatic hypoglycaemia, particularly at night.(3,4) This may be, in part, because those people who are at the greatest risk of hypoglycaemia a…”
BackgroundBruttomesso, D., Crazzolara, D., Maran, A., Costa, S., Dal Pos, M., Girelli, A., Lepore, G., Aragona, M., Iori, E., Valentini, U., et al. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02365.x · Cited by 136 · cited 2×
“One new trial has been published since the last appraisal by NICE: Bruttomesso et al.(16) This trial recruited 42 patients already well controlled on the pump (mean HbA1c 7.”
MethodIntensive Insulin Therapy With Insulin Lispro
Tsui, E., Barnie, A., Ross, S., Parkes, R., & Zinman, B. (2001) · Diabetes Care · doi:10.2337/diacare.24.10.1722 · Cited by 131
Monami, M., Lamanna, C., Marchionni, N., & Mannucci, E. (2009) · Acta Diabetologica · doi:10.1007/s00592-009-0132-5 · Cited by 123 · cited 1×
“A recent meta-analysis by Monami et al.(18) concluded that ‘available data justify the use of CSII for basal-bolus insulin therapy in type 1 diabetic patients unsatisfactorily controlled with MDI’.”
MethodBolli, G. B., Kerr, D., Thomas, R., Torlone, E., Sola-Gazagnes, A., Vitacolonna, E., Selam, J. L., & Home, P. D. (2009) · Diabetes Care · doi:10.2337/dc08-1874 · Cited by 119
The EQuality1 Study Group—evaluation of QUALITY of life and costs in diabetes Type 1. Writing committee:, Nicolucci, A., Maione, A., Franciosi, M., Amoretti, R., Busetto, E., Capani, F., Bruttomesso, D., Di Bartolo, P., Girelli, A., et al. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02346.x · Cited by 117
Elliott, J., Jacques, R. M., Kruger, J., Campbell, M. J., Amiel, S. A., Mansell, P., Speight, J., Brennan, A., & Heller, S. R. (2014) · Diabetic Medicine · doi:10.1111/dme.12441 · Cited by 112
Self-citationAlva, M., Gray, A., Mihaylova, B., & Clarke, P. (2014) · Health Economics · doi:10.1002/hec.2930 · Cited by 109
Pedersen‐Bjergaard, U., Kristensen, P. L., Beck‐Nielsen, H., Nørgaard, K., Perrild, H., Christiansen, J. S., Jensen, T. J., Hougaard, P., Parving, H., Thorsteinsson, B., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70073-7 · Cited by 103
(2017) · BMJ · doi:10.1136/bmj.j1285 · Cited by 102 · cited 12×
“5%) and dropout rate of 15%, suggested that the trial would require at least 240 participants with primary outcome data at 2 years in order to preserve power of at least 85%.(23) METHODS”
BackgroundMethodInfluentialBrinchmann-Hansen, O., Dahl-Jorgensen, K., Hanssen, K. F., & Sandvik, L. (1988) · Archives of Ophthalmology · doi:10.1001/archopht.1988.01060140402041 · Cited by 96
Roze, S., Valentine, W. J., Zakrzewska, K. E., & Palmer, A. J. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01576.x · Cited by 96
Colquitt, J., Royle, P., & Waugh, N. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.01018.x · Cited by 95
Self-citationRisk analysis and risk adapted on-site monitoring in noncommercial clinical trials
Brosteanu, O., Houben, P., Ihrig, K., Ohmann, C., Paulus, U., Pfistner, B., Schwarz, G. L., Strenge-Hesse, A., & Zettelmeyer, U. (2009) · Clinical Trials · doi:10.1177/1740774509347398 · Cited by 95 · cited 1×
“(DH)/MHRA report on risk-adapted approaches to the management of clinical trials of investigational medicinal products(93) (based on the classification by Brosteanu et al.(94)), the REPOSE Trial was classified as a Type A study: no higher than the risk of standard medical care.”
BackgroundLowes, L., Eddy, D., Channon, S., McNamara, R. L., Robling, M. R., & Gregory, J. W. (2014) · Journal of Pediatric Nursing · doi:10.1016/j.pedn.2014.09.006 · Cited by 94
Cederholm, J., Eeg-Olofsson, K., Eliasson, B., Zethelius, B., Gudbjörnsdottir, S., & Register, O. B. O. T. S. N. D. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03342.x · Cited by 90
A Measure of Treatment Satisfaction Designed Specifically for People with Insulin‐dependent Diabetes
Lewis, K. S., Bradley, C., Knight, G., Boulton, A. J. M., & Ward, J. D. (1988) · Diabetic Medicine · doi:10.1111/j.1464-5491.1988.tb00976.x · Cited by 86
Garg, S. K., Voelmle, M. K., Beatson, C. R., Miller, H. A., Crew, L. B., Freson, B. J., & Hazenfield, R. M. (2011) · Diabetes Care · doi:10.2337/dc10-1852 · Cited by 85
Bruttomesso, D., Pianta, A., Crazzolara, D., Scaldaferri, E., Lora, L., Guarneri, G., Mongillo, A., Gennaro, R., Miola, M., Moretti, M., et al. (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00750.x · Cited by 83
A simple imputation algorithm reduced missing data in SF-12 health surveys
Perneger, T., & Burnand, B. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.06.005 · Cited by 82 · cited 1×
“When the questionnaires were only partially completed, missing items were imputed using a single imputation procedure based on the mean calculated from complete items on that domain.(136) The scores were standardised and scaled to range from 0 to 100, with higher scores representing better outcomes.”
MethodRoze, S., Smith‐Palmer, J., Valentine, W., de Portu, S., Nørgaard, K., & Pickup, J. C. (2015) · Diabetic Medicine · doi:10.1111/dme.12792 · Cited by 77 · cited 2×
“A recent systematic review on the cost-effectiveness of pump therapy in different countries identified four studies that were conducted in a UK setting, three of which presented an ICER.(19) The base-case ICERs in these studies ranged from £37,712 to £11,461 per QALY gained.”
BackgroundHome, P. D., Capaldo, B., Burrin, J. M., Worth, R., & Alberti, K. G. (1982) · Diabetes Care · doi:10.2337/diacare.5.5.466 · Cited by 75
Scuffham, P., & Carr, L. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.00991.x · Cited by 73 · cited 1×
“They identified four cost-effectiveness studies in the UK setting, three of which presented an incremental cost-effectiveness ratio (ICER).(9,14,20,21) The ICERs in these studies were £11,461 per quality-adjusted life-year (QALY) gained, £25,648 per QALY gained and £37,712 per QALY gained.”
BackgroundRiemsma, R., Corro Ramos, I., Birnie, R., Büyükkaramikli, N., Armstrong, N., Ryder, S., Duffy, S., Worthy, G., Al, M., Severens, J., et al. (2016) · Health Technology Assessment · doi:10.3310/hta20170 · Cited by 73
Recent advances in treatment of youth with Type 1 diabetes: better care through technology
Tamborlane, W. V., Bonfig, W., & Boland, E. (2001) · Diabetic Medicine · doi:10.1046/j.1464-5491.2001.00626.x · Cited by 71 · cited 1×
“insulin continuously under the skin via a small plastic tube and cannula [continuous subcutaneous insulin infusion (CSII)].(6,7) These devices are filled with reservoirs of quick-acting insulin only (usually an insulin analogue), which provides insulin replacement by delivering both the mealtime and background insulin.”
BackgroundPeyrot, M., & Rubin, R. R. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2008.0002 · Cited by 68
Secnik Boye, K., Matza, L. S., Oglesby, A., Malley, K., Kim, S., Hayes, R. P., & Brodows, R. (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-80 · Cited by 68
Peasgood, T., Brennan, A., Mansell, P., Elliott, J., Basarir, H., & Kruger, J. (2016) · Medical Decision Making · doi:10.1177/0272989x16658660 · Cited by 66 · cited 2×
“2 of the model were considered for updating by the new information presented in Peasgood et al.(112) and Beaudet et al.”
MethodSelf-citationthe UK NIHR DAFNE Study Group, Rankin, D., Cooke, D. D., Elliott, J., Heller, S. R., & Lawton, J. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-652 · Cited by 63
Self-citationCurrie, C. J., Poole, C. D., Woehl, A., Morgan, C. L., Cawley, S., Rousculp, M. D., Covington, M. T., & Peters, J. R. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.02057.x · Cited by 61
Lawton, J., Kirkham, J., Rankin, D., White, D. A., Elliott, J., Jaap, A., Smithson, W. H., Heller, S., & the REPOSE Group (2016) · Diabetic Medicine · doi:10.1111/dme.12879 · Cited by 61 · cited 1×
“For similar reasons, educators also described how, despite meeting clinical criteria for pump referral, they had not generally recommended individuals for pump therapy in routine clinical practice if they had a poor history of diabetes self-management, were older or were less academically able.(157) This was a result…”
BackgroundSelf-citationLawton, J., Rankin, D., Cooke, D. D., Clark, M., Elliot, J., & Heller, S. R. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.11.007 · Cited by 60
Self-citationConducting qualitative research within Clinical Trials Units: Avoiding potential pitfalls
Cooper, C., O'Cathain, A., Hind, D., Adamson, J., Lawton, J., & Baird, W. (2014) · Contemporary Clinical Trials · doi:10.1016/j.cct.2014.06.002 · Cited by 60 · cited 1×
“It is common practice for qualitative research to be undertaken with patients and staff who are involved in clinical trials.(161,162) This research usually takes place during a trial’s pilot or early phases to improve recruitment, patients’ understanding of trial processes and the solicitation of informed consent.”
MethodSelf-citationLawton, J., Fox, A., Fox, C., & Kinmonth, A. L. (2003) · Europe PMC (PubMed Central) · Cited by 58
Self-citationPickup, J. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02574.x · Cited by 58
Gunn, D., & Mansell, P. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03525.x · Cited by 57
Self-citationBeato‐Víbora, P., Yeoh, E., Rogers, H., Hopkins, D., Amiel, S. A., & Choudhary, P. (2015) · Diabetic Medicine · doi:10.1111/dme.12869 · Cited by 55 · cited 1×
“Two studies(56,59) were excluded: Beato-Vibora et al.(56) was not included because fewer than one-quarter of the individuals in the initial sample had follow-up data for any given year; Clements et al.”
BackgroundSelf-citationLepore, G., Dodesini, A. R., Nosari, I., & Trevisan, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1321 · Cited by 55 · cited 3×
“Lepore et al.(44) report HbA1c only at baseline and 12 months.”
BackgroundInfluentialLawton, J., Rankin, D., Cooke, D. D., Elliott, J., Amiel, S., Heller, S., & for the UK NIHR DAFNE Study Group (2013) · Diabetic Medicine · doi:10.1111/dme.12007 · Cited by 54
Self-citationChiasson, J. L., Ducros, F., Poliquin-Hamet, M., Lopez, D., Lecavalier, L., & Hamet, P. (1984) · Diabetes Care · doi:10.2337/diacare.7.4.331 · Cited by 54
Lawton, J., Jenkins, N., Darbyshire, J. L., Farmer, A. A., Holman, R. R., & Hallowell, N. (2011) · Social Science & Medicine · doi:10.1016/j.socscimed.2011.11.012 · Cited by 53 · cited 1×
“Qualitative research has also been undertaken during trial delivery to explore adherence to trial protocols and treatments, and aid interpretation of trial findings.(169,170) Although the closeout of a trial potentially presents challenges for both patients and health professionals, especially when patients may be req…”
MethodSelf-citationHeller, S., Lawton, J., Amiel, S., Cooke, D., Mansell, P., Brennan, A., Elliott, J., Boote, J., Emery, C., Baird, W., et al. (2014) · Programme Grants for Applied Research · doi:10.3310/pgfar02050 · Cited by 53
Self-citationIntensive Conventional and Insulin Pump Therapies in Adult Type I Diabetes: A Crossover Study
NATHAN, D. M., LOU, P., & AVRUCH, J. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-1-31 · Cited by 52
Nixon, R., & Pickup, J. C. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0192 · Cited by 51
Lawton, J., Kirkham, J., White, D., Rankin, D., Cooper, C., & Heller, S. (2015) · Trials · doi:10.1186/1745-6215-16-3 · Cited by 51
Self-citationConfidence Intervals for Rank Statistics: Percentile Slopes, Differences, and Ratios
Newson, R. (2006) · The Stata Journal: Promoting communications on statistics and Stata · doi:10.1177/1536867x0600600404 · Cited by 48
Lawton, J., Rankin, D., Cooke, D. D., Elliott, J., Amiel, S. A., & Heller, S. R. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.09.024 · Cited by 47
Self-citationSmith, C. T., Hopkins, C., Sydes, M., Woolfall, K., Clarke, M., Murray, G., & Williamson, P. (2015) · Trials · doi:10.1186/1745-6215-16-s2-o1 · Cited by 45
Point: Are Insulin Pumps Underutilized in Type 1 Diabetes? Yes
Pickup, J. C. (2006) · Diabetes Care · doi:10.2337/dc06-0011 · Cited by 41
Thomas, R. M., Aldibbiat, A., Griffin, W., Cox, M. A. A., Leech, N. J., & Shaw, J. A. M. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02196.x · Cited by 40 · cited 2×
“The Thomas et al.(15) trial was a pilot, with only seven patients per arm.”
BackgroundMethodQuirós, C., Giménez, M., Ríos, P., Careaga, M., Roca, D., Vidal, M., & Conget, I. (2016) · Diabetic Medicine · doi:10.1111/dme.13094 · Cited by 40 · cited 1×
“There was a marked reduction in severe hypoglycaemia.(64)”
BackgroundDinneen, S. F., O’Hara, M. C., Byrne, M., Smith, D., Courtney, C. H., McGurk, C., Heller, S. R., Newell, J., Bargary, N., Breen, C., et al. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.01.017 · Cited by 40 · cited 1×
“Research into DAFNE education has also been undertaken by the Irish DAFNE group.(81) They carried out a large randomised trial of group follow-up compared with individual clinic visits for patients who had BOX 1 National Institute for Health and Care Excellence guidance on the MiniMed Veo insulin pump(77)”
MethodSelf-citationOrr, C. J., Hopman, W. M., Yen, J. L., & Houlden, R. L. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0131 · Cited by 39
Thokala, P., Kruger, J., Brennan, A., Basarir, H., Duenas, A., Pandor, A., Gillett, M., Elliott, J., & Heller, S. (2014) · Diabetic Medicine · doi:10.1111/dme.12371 · Cited by 39
Self-citationThe UK service level audit of insulin pump therapy in adults
White, H. D., Goenka, N., Furlong, N. J., Saunders, S., Morrison, G., Langridge, P., Paul, P., Ghatak, A., & Weston, P. J. (2013) · Diabetic Medicine · doi:10.1111/dme.12325 · Cited by 39
Carlsson, B.-M., Attvall, S., Clements, M. A., Gumpeny, S. R., Pivodic, A., Sternemalm, L., & Lind, M. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0286 · Cited by 38 · cited 3×
“was excluded because it was a subgroup analysis of the data presented by Carlsson et al.(58) As such, if Carlsson et al.”
BackgroundMethodInfluentialA Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus
Henriksson, M., Jindal, R., Sternhufvud, C., Bergenheim, K., Sörstadius, E., & Willis, M. S. (2016) · PharmacoEconomics · doi:10.1007/s40273-015-0374-8 · Cited by 38 · cited 1×
“Most health economic models of T1DM estimate the cost-effectiveness by primarily modifying HbA1c levels, which subsequently affect the risk of diabetic complications.(88) However, it is important to note that HbA1c may not have fallen in patients who entered the trial with low baseline levels of HbA1c, but who might h…”
BackgroundSaurbrey, N., Arnold‐Larsen, S., Møller‐Jensen, B., & Kühl, C. (1988) · Diabetic Medicine · doi:10.1111/j.1464-5491.1988.tb00962.x · Cited by 37
Casey, D., Murphy, K., Lawton, J., White, F. F., & Dineen, S. (2011) · BMC Public Health · doi:10.1186/1471-2458-11-672 · Cited by 36
Self-citationNixon, R., Folwell, R., & Pickup, J. C. (2014) · Diabetic Medicine · doi:10.1111/dme.12486 · Cited by 32 · cited 1×
“Nixon et al.(62) reported a study of 35 patients on pump therapy.”
BackgroundJf, B., Nielsen, O. H., Pedersen, O. B., & Beck‐Nielsen, H. (1987) · PubMed · Cited by 32
Rosenlund, S., Hansen, T. W., Andersen, S., & Rossing, P. (2015) · Diabetic Medicine · doi:10.1111/dme.12950 · Cited by 31 · cited 1×
“Rosenlund et al.(65) from Denmark looked at the effects of 4 years of pump therapy on albuminuria compared with an unmatched group on MDI.”
MethodRankin, D., Barnard, K. D., Elliott, D., Cooke, D. D., Heller, S. R., Gianfrancesco, C., Taylor, C., Lawton, J., & the UK NIHR DAFNE Study Group (2014) · Journal of Clinical Nursing · doi:10.1111/jocn.12539 · Cited by 31
Self-citationLawton, J., Jenkins, N., Darbyshire, J. L., Holman, R. R., Farmer, A. J., & Hallowell, N. (2011) · Trials · doi:10.1186/1745-6215-12-108 · Cited by 31 · cited 1×
“Qualitative research has also been undertaken during trial delivery to explore adherence to trial protocols and treatments, and aid interpretation of trial findings.(169,170) Although the closeout of a trial potentially presents challenges for both patients and health professionals, especially when patients may be req…”
MethodSelf-citationLawton, J., Kirkham, J., Rankin, D., Barnard, K., Cooper, C. L., Taylor, C., Heller, S., & Elliott, J. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.09.011 · Cited by 30 · cited 2×
“Others still reported liking the data storage facility, as this reduced the burden of maintaining a paper diary.(155)”
BackgroundSelf-citationHaakens, K., Hanssen, K. F., Dahl‐Jørgensen, K., Vaaler, S., Aagenaes, Ö., & Mosand, R. (1990) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1990.tb00263.x · Cited by 30
Elliott, D., Rankin, D., Jacques, R., Lawton, J., Emery, C., Campbell, M. J., Dixon, S., & Heller, S. R. (2014) · Diabetic Medicine · doi:10.1111/dme.12621 · Cited by 28 · cited 2×
“A programme of work has included a trial comparing the 5-day course in 1 week with 1 day a week for 5 weeks, which found little difference in outcomes.(78)”
MethodSelf-citationClements, M., Matuleviciene, V., Attvall, S., Ekelund, M., Pivodic, A., Dahlqvist, S., Fahlén, M., Haraldsson, B., & Lind, M. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0139 · Cited by 27
Eborall, H. C., Dallosso, H. M., Daly, H., Martin-Stacey, L., & Heller, S. R. (2014) · Trials · doi:10.1186/1745-6215-15-15 · Cited by 27
Self-citationMcEwan, P. C., Poole, C., Tetlow, T., Holmes, P., & Currie, C. J. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x167561 · Cited by 25
White, D. A., Waugh, N. R., Elliott, J., Lawton, J., Barnard-Kelly, K. D., Campbell, M. J., Dixon, S., & Heller, S. R. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-006204 · Cited by 22 · cited 2×
“On closeout, each REPOSE centre was advised (as per the trial’s SOP for closeout; see Appendix 15) to make their own clinical decisions about which patients should remain on a pump and who should revert to a MDI regimen, with centres having to find local funding for patients who remained on pump therapy.(86) It was al…”
MethodSelf-citationLee, S. W., Sweeney, T., Clausen, D., Kolbach, C., Hassen, A., Firek, A. F., Brinegar, C. H., & PETROFSKY, J. S. (2007) · Journal of Diabetes Science and Technology · doi:10.1177/193229680700100313 · Cited by 21
A hermeneutic phenomenological study of why adults with type 1 diabetes choose to discontinue CSII
Hayes, M., Frearson, S., Keller, C., Cartmale, A., & Lewis-Hayes, S. (2011) · European Diabetes Nursing · doi:10.1002/edn.167 · Cited by 21
Long-Term Metabolic Effects of Continuous Subcutaneous Insulin Infusion Therapy in Type 1 Diabetes
Cohen, N. D., Hong, E. S., Drie, C. V., Balkau, B., & Shaw, J. E. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0331 · Cited by 21 · cited 1×
“Cohen et al.(60) compared two cohorts from Melbourne in a non-randomised comparison.”
BackgroundLawton, J., White, D. A., Rankin, D., Elliott, D., Taylor, C., Cooper, C. L., Heller, S. R., & Hallowell, N. (2017) · Trials · doi:10.1186/s13063-017-1813-y · Cited by 20 · cited 2×
“A peer-reviewed journal article is in press.(173) DOI: 10.”
BackgroundSelf-citationLepore, G., Bruttomesso, D., Bonomo, M., Dodesini, A. R., Costa, S., Meneghini, E., Corsi, A. M., Nosari, I., & Trevisan, R. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02736.x · Cited by 17
Patient-reported outcomes and diabetes technology: a systematic review of the literature.
Rubin, R. R., & Peyrot, M. F. (2010) · PubMed · Cited by 17
Schmitz, A., Christiansen, J. S., Ck, C., Hermansen, K., & Mogensen, C. E. (1989) · PubMed · Cited by 15
Is it any good? The evaluation of therapy by participants in a clinical trial
Wynne, A. (1989) · Social Science & Medicine · doi:10.1016/0277-9536(89)90069-5 · Cited by 14 · cited 1×
“The limited work undertaken to date suggests that patients may experience a form of trial bereavement on closeout,(171) and some may wish to continue using trial treatment(s) despite the trial failing to show clinical benefit.(172) How staff address closeout issues with patients, and what their own information and sup…”
BackgroundEngel, L., & Cummins, R. A. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.11.023 · Cited by 13
Schottenfeld-Naor, Y., Galatzer, A., Karp, M., JOSEFSBERG, Z., & Laron, Z. (1985) · PubMed · Cited by 12
Heinemann, L., & Hermanns, N. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815597918 · Cited by 10 · cited 1×
“has been strongly criticised by the German Institute for Quality and Efficiency in Healthcare [Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)], as reported by Heinemann and Hermanns.(76)”
MethodHoogma, R. P. L. M., Hoekstra, J. B. L., Michels, B. P. J., & Levi, M. M. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(06)70019-5 · Cited by 9
Wardle, K., Murphy, D., Ireland, L., Holbeck, C., Davidson, C. S., Wen, L. M., & Rissel, C. E. (2011) · Australian journal of advanced nursing · doi:10.37464/2011.282.1681 · Cited by 4
Cole, F., Cullum, R., Cooke, D. D., Taylor, C., Murphy, H. R., & Mansell, P. (2013) · Open Research (University of Surrey) · doi:10.1111/dme.12091_2 · Cited by 3
Self-citationMaran, A., Tiengo, A., Avogaro, A., Bruttomesso, D., Crazzolara, D., M., N., S., C., & M., D. P. (2005) · Padua Research Archive (University of Padova) · Cited by 2
Mansell, P., Cullum, R., Cole, F., Taylor, C., Cooke, D. D., & Murphy, H. R. (2013) · Open Research (University of Surrey) · Cited by 1
Self-citationCarlone, A., Phd, R. B., Cipolloni, L., C, G., C, G., & G, L. (2011) · IRIS Research product catalog (Sapienza University of Rome) · Cited by 1
Research works printed but not linked: 24
- NICE, 2008, Continuous Subcutaneous Insulin Infusion for the Treatment of Diabetes Mellitus
- NICE, 2013, Guide to the Methods of Technology Appraisal 2013
- Ray, 2013, Dose adjustment for normal eating (DAFNE) structured education reduces progression to continuous subcutaneous insulin infusion (CSII) among patients being considered for insulin pump therapy at enrolment, Diabet Med, 30, 7
- Nosadini, 1988, Frequency of hypoglycaemic and hyperglycaemic-ketotic episodes during conventional and subcutaneous continuous insulin infusion therapy in IDDM, Diabetes Nutr Metab Clin Exp, 1, 289
- Bacon, 2014, The effectiveness and safety of continuous subcutaneous insulin infusion in a large adult cohort over a 10 year period, Ir J Med Sci, 1, S450
- NICE, 2016, Integrated sensor-dugmented pump therapy systems for managing blood glucose levels in type 1 diabetes (the MiniMed Paradigm Veo system and the Vibe and G4 PLATINUM CGM system)
- Zijlstra, 2015, Faster-acting insulin aspart by continuous subcutaneous insulin infusion: earlier exposure and greater early pharmacokinetic/pharmacodynamic effects vs. insulin aspart, Diabetologia, 1, S452
- Medical Research Council/DH/MHRA Joint Project, 2011, Risk-adapted Approaches to the Management of Clinical Trials of Investigational Medicinal Products
- Curtis, 2014, Unit Costs of Health and Social Care 2014
- DAFNE, 2012, DAFNE Fact Sheet Six
- Department of Health, 2014, NHS Reference Costs 2013 to 2014
- Department of Health, 2013, NHS Reference Costs 2012 to 2013
- Joint Formulary Committee, British National Formulary (online)
- Health and Social Care Information Centre, 2015, Prescription Cost Analysis England 2014
- London New Drugs Group, 2013, Comparative Table of Insulin Pumps
- Palmer JL. Cost-effectiveness of Angiotensin-converting Enzyme Inhibitors for the Prevention of Cardiovascular and End-stage Renal Disease in Patients with Type 1 Diabetes. 2012. PhD thesis. Sheffield: University of Sheffield; 2012.
- Joint Formulary Committee, 2012, British National Formulary
- Department of Health, 2011, NHS Reference Costs 2010–11
- The WHOQOL Group, 1996, WHOQOL-Bref: Introduction, Administration, Scoring and Generic Version of the Assessment
- Office for National Statistics, 2010, Standard occupational classification 2010
- Scottish Government, 2012, Scottish Index of Multiple Deprivation 2012
- NICE, Type 1 Diabetes in Adults: Diagnosis and Management
- Health and Social Care Information Centre, 2014, National Diabetes Audit 2012–13. Report 1: Care Processes and Treatment Targets
- SIGN, 2013, Management of Diabetes: A National Clinical Guideline
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Effects of sotagliflozin added to insulin in patients with type 1 diabetes
Garg, S. K., Henry, R. R., Banks, P., Buse, J. B., Davies, M. J., Fulcher, G. R., Pozzilli, P., Gesty-Palmer, D., Lapuerta, P., Simó, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708337 · Cited by 417
Grunberger, G., Sherr, J., Allende, M., Blevins, T., Bode, B., Handelsman, Y., Hellman, R., Lajara, R., Roberts, V. L., Rodbard, D., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.04.008 · Cited by 288
Buse, J. B., Garg, S. K., Rosenstock, J., Bailey, T. S., Banks, P., Bode, B. W., Danne, T., Kushner, J. A., Lane, W. S., Lapuerta, P., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0343 · Cited by 234
“can increase DKA risk through operational or mechanical failures (35,36).”
BackgroundScott, G., Gillon, T. E., Pels, A., von Dadelszen, P., & Magee, L. A. (2022) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2020.08.018 · Cited by 159
Metadata
- Authors
- Heller, S., White, D., Lee, E., Lawton, J., Pollard, D., Waugh, N., Amiel, S., Barnard, K., Beckwith, A., Brennan, A., Campbell, M., Cooper, C., Dimairo, M., Dixon, S., Elliott, J., Evans, M., Green, F., Hackney, G., Hammond, P., Hallowell, N., Jaap, A., Kennon, B., Kirkham, J., Lindsay, R., Mansell, P., Papaioannou, D., Rankin, D., Royle, P., Smithson, W. H., & Taylor, C.
- Affiliations
- University of Sheffield (GB)
- University of Edinburgh (GB)
- University of Warwick (GB)
- King's College London (GB)
- University of Southampton (GB)
- King's College Hospital NHS Foundation Trust (GB)
- Academic Unit of Diabetes, Endocrinology and Metabolism, University of Sheffield, Sheffield, UK
- University of Cambridge (GB)
- Dumfries and Galloway Royal Infirmary (GB)
- Harrogate and District NHS Foundation Trust (GB)
- Edinburgh Royal Infirmary (GB)
- NHS Greater Glasgow and Clyde (GB)
- University of Glasgow (GB)
- Nottingham University Hospitals NHS Trust (GB)
- University College Cork (IE)
- Sheffield Teaching Hospitals NHS Foundation Trust (GB)
- Corresponding author
- Heller, Simon
- ORCID
- Heller, Simon
- White, David
- Lee, Ellen
- Lawton, Julia
- Pollard, Daniel
- Waugh, Norman
- Amiel, Stephanie
- Brennan, Alan
- Campbell, Michael
- Cooper, Cindy
- Dimairo, Munyaradzi
- Dixon, Simon
- Evans, Mark
- Hackney, Gemma
- Hammond, Peter
- Hallowell, Nina
- Jaap, Alan
- Kennon, Brian
- Kirkham, Jackie
- Lindsay, Robert
- Papaioannou, Diana
- Rankin, David
- Royle, Pamela
- Venue
- Health Technology Assessment
- Published
- 2017-04
- Volume
- 21
- Issue
- 20
- Pages
- 1-278
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- PMC
- PMC5421095
- OpenAlex
- W2607776465
- Cited by
- 73
- References
- 160
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 7 · 2023: 5 · 2022: 9 · 2021: 13 · 2020: 10 · 2019: 9 · 2018: 12 · 2017: 4
- FWCI
- 7.56
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Health Technology Assessment (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Warwick Research Archive Portal (University of Warwick) (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Arrow@dit (Dublin Institute of Technology) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Cork Open Research Archive (University College Cork, Ireland) (submittedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Funders
- Health Technology Assessment programme (08/107/01)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 1 diabetes, insulin pump therapy, multiple daily insulin injections, HbA1c, hypoglycemia, cost-effectiveness, quality of life, fear of hypoglycemia, insulin aspart, insulin analogues, diabetes self-management education, emotional well-being
- MeSH terms
- Adolescent, Adult, Aged, Blood Glucose, Body Weight, Cost-Benefit Analysis, Diabetes Mellitus, Type 1, Dose-Response Relationship, Drug, Female, United Kingdom, Glycated Hemoglobin, Humans, Hypoglycemia, Insulin, Insulin Infusion Systems, Male, Middle Aged, Proteinuria, Quality of Life, State Medicine, Technology Assessment, Biomedical, Diabetic Ketoacidosis, Quality-Adjusted Life Years, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.